Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Haematologica. 2019 May;104(5):862-864. doi: 10.3324/haematol.2018.214445.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases

Substances

  • Protein Kinase Inhibitors
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases